Astellas
FDA Approves Extended Dosing for Astellas’ Izervay, Intensifying Competition in Geographic Atrophy Treatment
Izervay, Astellas, FDA approval, extended dosing, geographic atrophy, age-related macular degeneration, Syfovre, Apellis, eye treatment
FDA Approves Extended Dosing for Astellas’ Izervay in Geographic Atrophy Treatment
Izervay, avacincaptad pegol, geographic atrophy, age-related macular degeneration, FDA approval, extended dosing, Astellas Pharma
Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review
Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology
Astellas and Sangamo Therapeutics Partner to Enhance Neurological Gene Therapy with STAC-BBB Capsid
Astellas, Sangamo Therapeutics, STAC-BBB capsid, neurological gene therapy, genomic medicines, blood-brain barrier penetration
FDA Issues Complete Response Letter to Astellas for IZERVAY Supplemental New Drug Application
FDA, Astellas, IZERVAY, geographic atrophy, age-related macular degeneration, Complete Response Letter, supplemental New Drug Application
Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay
Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol
Astellas Secures FDA Approval for Vyloy, a First-in-Class Claudin-Targeted Therapy for Gastric Cancers
Astellas, Vyloy, FDA Approval, Claudin 18.2, Gastric Cancer, Gastroesophageal Junction Cancer, HER2-negative, Zolbetuximab
Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan
Astellas, Universal Cells, layoffs, Seattle, Japan, cell therapy, biotech
Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells
Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy
Astellas Launches First Direct-to-Consumer Campaign for IZERVAY, Highlighting Its Potential to Slow Geographic Atrophy Progression
IZERVAY, geographic atrophy, age-related macular degeneration, direct-to-consumer campaign, Astellas Pharma